Immunosuppressive drug therapy for preventing rejection following lung transplantation in cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 12, 2013, Pages

  Saldanha, Ian J ^a   Akinyede, Oluwaseun ^b   Mckoy, Naomi A ^c   Robinson, Karen A ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORINE; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLATE MOFETIL; RAPAMYCIN; TACROLIMUS;

CARDIOTOXICITY; CYSTIC FIBROSIS; DIABETES MELLITUS; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG FUNCTION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; META ANALYSIS; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; GRAFT REJECTION;

GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION;

EID: 84897368235     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009421.pub2     Document Type: Review

References (37)

1. Bhorade S, Ahya VN, Baz MA, Valentine VG, Arcasoy SM, Love RB, et al.Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation. American Journal of Respiratory and Critical Care Medicine 2011;183(3):379-87. [PUBMED: 20833822]
2. Ghassemieh B, Ahya VN, Baz MA, Valentine VG, Arcasoy SM, Love RB, et al.Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation. The Journal of Heart and Lung Transplantation: the official publication of the International Society for Heart Transplantation 2013;32(7):701-6. [PUBMED: 23664526]
3. GrovesS, GalazkaM, Johnson B, Corcoran T, Verceles A, Britt E, et al.Inhaled cyclosporine and pulmonary function in lung transplant recipients. Journal of Aerosol Medicine and Pulmonary Drug Delivery 2010;23(1):31-9.
4. Iacono AT, Johnson BA, Grgurich WF, Corcoran TE, Youssef G, Smith-Seiler DA, et al.A randomized trial of inhalational cyclosporine in lung transplant recipients [abstract]. Pediatric Pulmonology 2004;38 Suppl 27:318. [CFGD Register: CO37; MEDLINE: 96204950]
5. IaconoAT, Johnson BA, Grgurich WF, Youssef JG, Corcoran TE, et al.A randomized trial of inhaledcyclosporinein lung-transplant recipients. New England Journal of Medicine 2006;354(2):141-50.
6. Aurora P, Edwards LB, Christie JD, Dobbels F, Kirk R, Rahmel AO, et al.Registry of the International Society for Heart and Lung Transplantation: Twelfth Official Pediatric Lung and Heart/LungTransplantation Report - 2009. Journal of Heart and Lung Transplantation 2009;28(10):1023-30.
7. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dobbels F, Kirk R, et al.The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth adult lung and heart-lung transplant report--2011. The Journal of Heart and Lung Transplantation: the official publication of the International Society for Heart Transplantation 2011;30(10):1104-22. [PUBMED: 21962018]
8. Cosimi AB, Burton RC, Colvin RB, Goldstein G, Delmonico FL, LaQuaglia MP, et al.Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981;32(6):535-9.
9. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry Annual Data Report 2011. Cystic Fibrosis Foundation 2011.
10. Cystic Fibrosis Foundation. About Cystic Fibrosis: What you need to know. http://www.cff.org/AboutCF/ Last accessed October 14, 2013 2013.
11. Gee L, Abbott J, Conway S, Etherington C, Webb A. Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax 2000;55(11):946-54.
12. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
13. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2009. Available from www.cochrane-handbook.org.
14. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2009. Available from www.cochrane-handbook.org.
15. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2009. Available from www.cochrane-handbook.org.
16. Hopkins PM, Aboyoun CL, Chhajed PN, Malouf MA, Plit ML, Rainer SP, et al.Prospective analysis of 1, 235 transbronchial lung biopsies in lung transplant recipients. Journal of Heart and Lung Transplantation 2002;21(10):1062-7.
17. Hopkins PM, McNeil K. Evidence for immunosuppression in lung transplantation. Current Opinion in Organ Transplantation 2008;13(5):477-83.
18. International Society for Heart and Lung Transplantation. Registries - Heart/Lung Registries. http://www.ishlt.org/registries/heartLungRegistry.asp (accessed 14 October 2013).
19. Izquierdo J, Schoenbach V. The potential and limitations of data from population-based state cancer registries. American Journal of Public Health 2000;90(5):695-8.
20. Jaramillo A, Fernández FG, Kuo EY, Trulock EP, Patterson GA, Mohanakumar T. Immune mechanisms in the pathogenesis of bronchiolitis obliterans syndrome after lung transplantation. Pediatric Transplantation 2005;9(1):84-93.
21. King-Biggs MB. Acute pulmonary allograft rejection. Mechanisms, diagnosis, and management. Clinics in Chest Medicine 1997;18(2):301-10.
22. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, Williamson PR. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340(c365):637-40.
23. Knoop C, Haverich A, Fischer S. Immunosuppressive therapy after human lung transplantation. European Respiratory Monthly 2003;26:105-29.
24. Leonard MB, Szezech LA, Feldman HI. Design and Interpretation of Clinical Trials in Transplantation. In: Norman DJ, Turka LA editor(s). Primer on Transplantation. 2nd Edition. American Society of Transplantation, 2001:114-24.
25. Lischke R, Simonek J, Davidová R, Schützner J, Stolz AJ, Vojácek J, et al.Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin. Transplantation Proceedings 2007;39(1):205-12.
26. Nathan H, Pawlik T. Limitations of claims and registry data in surgical oncology research. Annals of Surgical Oncology 2007;15(2):415-23.
27. National Cancer Institute. Dictionary of Cancer Terms. http://www.cancer.gov/dictionary/?CdrID=45728. National Cancer Institute of the US National Institutes of Health, (accessed 03 December 2010).
28. U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. 2009 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1999-2008. U.S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD.
29. Paradis I, Yousem S, Griffith B. Airway obstruction and bronchiolitis obliterans after lung transplantation. Clinics in Chest Medicine 1993;14(4):751-63.
30. Penninga L, Penninga EI, Møller CH, Iversen M, Steinbrüchel DA, Gluud C. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2013, issue 5. [DOI: 10.1002/14651858.CD008817.pub2]
31. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135(6):1610-8.
32. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. New England Journal of Medicine 1996;335(3):179-88.
33. Ratjen F, Doring G. Cystic fibrosis. Lancet 2003;361(9358):681-9.
34. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
35. Rowe SM, Miller S, Sorscher EJ. Cystic Fibrosis. The New England Journal of Medicine 2005;352(19):1992-2001.
36. Wierda WG, Kipps TJ, Keating MJ. Novel immune-based treatment strategies for chronic lymphocytic leukemia. Journal of Clinical Oncology 2005;23(26):6325-32.
37. Yusen RD, Shearon TH, Qian Y, Kotloff R, Barr ML, Sweet S, et al.Lung Transplantation in the United States, 1999-2008. American Journal of Transplantation 2010;10(4 Pt 2):1047-68.